Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.
AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...
The boss of AstraZeneca has denied a rift with the Government after axing plans for a £450m vaccine factory in Liverpool ...
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...
AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site - Pascal Soriot, chief executive of AstraZeneca, ...